Compare Cart
  • Japanese
  • Korean
  • Traditional Chinese
  • Simplified Chinese
Cover Image
Market Research Report
Product code 
907352

In Situ Hybridization (ISH)
Published: | Global Industry Analysts, Inc. | 504 Pages | Delivery time: 1-2 business days

Price

Back to Top
In Situ Hybridization (ISH)
Published: February 1, 2022
Global Industry Analysts, Inc.
Content info: 504 Pages
Delivery time: 1-2 business days
  • Description
  • Table of Contents

What`s New for 2022?

» Global competitiveness and key competitor percentage market shares

» Market presence across multiple geographies - Strong/Active/Niche/Trivial

» Online interactive peer-to-peer collaborative bespoke updates

» Access to our digital archives and MarketGlass Research Platform

» Complimentary updates for one year

Global In Situ Hybridization (ISH) Market to Reach $1.1 Billion by 2026

In situ Hybridization represents one of the key DNA-based technologies in molecular biology and its related clinical areas. The technique facilitates in locating a known sequence of DNA or a gene of interest on a chromosome using radio labeled or biotinylated probes. Probes are unique DNA sequences that can either be artificially synthesized or isolated from an organism for locating a particular DNA sequence on a chromosome. The process involved in in situ hybridization is subjecting the cells to some kind of stress to denature the DNA, followed by incubation of the cells containing the denatured DNA in a solution containing labeled probes or sequences whose position on the chromosome is to be determined. In-situ hybridization helps in the precise localization of a specific nucleic acid segment in a histologic specimen.

Amid the COVID-19 crisis, the global market for In Situ Hybridization (ISH) estimated at US$846.6 Million in the year 2020, is projected to reach a revised size of US$1.1 Billion by 2026, growing at a CAGR of 5.8% over the analysis period. Fluorescence In Situ Hybridization (FISH), one of the segments analyzed in the report, is projected to grow at a 5.6% CAGR to reach US$885.4 Million by the end of the analysis period. After a thorough analysis of the business implications of the pandemic and its induced economic crisis, growth in the Chromogenic In Situ Hybridization (cish) segment is readjusted to a revised 6.2% CAGR for the next 7-year period. This segment currently accounts for a 28.6% share of the global In Situ Hybridization (ISH) market.

The U.S. Market is Estimated at $361 Million in 2021, While China is Forecast to Reach $79.5 Million by 2026

The In Situ Hybridization (ISH) market in the U.S. is estimated at US$361 Million in the year 2021. The country currently accounts for a 41.52% share in the global market. China, the world second largest economy, is forecast to reach an estimated market size of US$79.5 Million in the year 2026 trailing a CAGR of 7.1% through the analysis period. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 5% and 5.5% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 5.6% CAGR while Rest of European market (as defined in the study) will reach US$85.7 Million by the end of the analysis period.

The market is poised to post healthy growth over the coming years, driven by various favorable factors steering market expansion. Increasing incidence of cancer and genetic abnormalities, need for rapid disease diagnosis through genetic techniques, as well as higher funding (both public and private) leading to introduction of highly advanced cytogenetic techniques and their broadening applications are some of the key factors poised to contribute to future growth. Significant rise in target patient population across the world, and rising preference for CGH in clinical diagnosis, is expected to drive the market further, providing players with lucrative opportunities. Growing awareness levels of genetic disorders and expanding pool of research laboratories would be beneficial for cytogenetics solutions. Rise in incidence of cancer and the subsequent demand for personalized medicine, is likely to enhance market prospects in a major way.

Select Competitors (Total 38 Featured) -

  • Abbott Laboratories
  • Abnova Corporation
  • Advanced Cell Diagnostics, Inc.
  • Agilent Technologies Inc
  • Bio SB
  • Biocare Medical, LLC
  • BioGenex Laboratories
  • Bio-Techne Corporation
  • Genemed Biotechnologies, Inc.
  • Leica Biosystems Nussloch GmbH
  • Thermo Fisher Scientific
  • Merck KGaA
  • Oxford Gene Technologies
  • PerkinElmer Inc.
Product Code: MCP12547

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • In Situ Hybridization (ISH) - Global Key Competitors Percentage Market Share in 2022 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2022 (E)
    • Impact of Covid-19 and a Looming Global Recession
    • 2020 Marked as a Year of Disruption & Transformation
    • World Economic Growth Projections (Real GDP, Annual % Change) for 2019 to 2022
    • Clinical Diagnostics: Challenges and Opportunities Amid the Pandemic
    • Research Efforts Underway for Using ISH in COVID-19 Detection
    • ISH in Molecular Detection of COVID-19 Causing SARS-CoV-2
    • Immuno RNA Fluorescence ISH for Visualization of COVID-19 Causing SARS-CoV-2
    • French Research Team Develops CoronaFISH
    • In Situ Hybridization: A Prelude
    • Future Prospects Remain Favorable for Insitu Hybridization
    • Chromogenic ISH: Gaining Over FISH
    • FISH Technology Continues to Find Favor
    • How is FISH Better than Conventional Techniques?
    • Probe Types and Application
    • Fluorescent In Situ Hybridization Emerges as Cytological Tool of Choice for Plethora of Scientific Applications
    • Recent Market Activity
    • World Brands
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Incidence of Cancer Drives the Demand for In-situ Hybridization
    • Breakdown of Total Number of Cancer Cases by Region: 2020
    • Breakdown of Total Number of Cancer Cases by Type: 2020
    • Diverse Applications of FISH Technology in Oncology
    • Growing Demand for Targeted Therapies in Cancer Treatment Presents Lucrative Opportunities
    • Growing Number of Genetic Disorders and Emphasis on Genetic Testing Bodes Well for the Growth of ISH Market
    • List of Genetic Disorders by Event, Genetic Manifestation and Prevalence
    • Top Ten Genetic Diseases Worldwide
    • Rise in Prenatal Testing Drives Opportunities
    • FISH in Detection of Prenatal Genetic Abnormalities
    • In Situ Hybridization Advances Present Perfect Tools to Detect Genetic Anomalies
    • Uptrend in Companion Diagnostics Market Augurs Well
    • World Companion Diagnostics Market (in US$ Million) for the Years 2019, 2021, 2023 & 2025
    • Companion Diagnostics Lead the Way to Personalized Medicine
    • Global Personalized Medicine Market: Revenues in US$ Million for the Years 2019, 2021, 2023 and 2025
    • State-Sponsored Molecular Research Initiatives Bode Well for Market Growth
    • Increasing Research on Application of ISH in infectious Disease Diagnostics to Drive Growth
    • Infection Rates of Viruses ((per infected person)) Involved in Outbreaks Worldwide: 2020
    • Infectious Diseases Related Mortality High Among Children Below 5 Years: Breakdown of Leading Causes of Death in Children Below 5 Years (in %) Cause % Share
    • Global Number of Deaths Caused Due to Communicable Diseases (In 000s)
    • FISH in Detection of Microbiological Pathogens
    • Growth in In-vitro Diagnostics (IVD) for Diagnosis of Chronic Diseases Promise Opportunities
    • High Demand for IVD Devices Promises Opportunities for FISH Probes: Global IVD Instruments Market (In US$ Billion) for the Years 2018, 2020, 2022, 2024 & 2027
    • Rising R&D Investments in the Biotech Sector Drives Gains
    • Emergence of Automated Diagnostic Kits
    • Novel Approach of Highly-Multiplexed FISH for In-Situ Genomics
    • Technology Advancements & Improvements Bolster Growth
    • Rise in Healthcare Expenditure to Drive Growth
    • World Healthcare Expenditure (In US$ Billion) for the Years 2017-2023
    • Healthcare Costs as a % of GDP by Country for the Years 2020 & 2023
    • Ageing Demographics to Drive Demand
    • Elderly Healthcare Expenditure as a % of GDP
    • Global Aging Population Statistics for the 65+ Age Group in Million by Geographic Region for the Years 2019, 2025, 2035 and 2050
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Recent Past, Current & Future Analysis for Fluorescence In Situ Hybridization (FISH) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 2: World Historic Review for Fluorescence In Situ Hybridization (FISH) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 3: World 15-Year Perspective for Fluorescence In Situ Hybridization (FISH) by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2021 & 2027
    • TABLE 4: World Recent Past, Current & Future Analysis for Chromogenic In Situ Hybridization (CISH) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 5: World Historic Review for Chromogenic In Situ Hybridization (CISH) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 6: World 15-Year Perspective for Chromogenic In Situ Hybridization (CISH) by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2021 & 2027
    • TABLE 7: World Recent Past, Current & Future Analysis for Cancer Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 8: World Historic Review for Cancer Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 9: World 15-Year Perspective for Cancer Diagnostics by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2021 & 2027
    • TABLE 10: World Recent Past, Current & Future Analysis for Immunology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 11: World Historic Review for Immunology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 12: World 15-Year Perspective for Immunology by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2021 & 2027
    • TABLE 13: World Recent Past, Current & Future Analysis for Neuroscience by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 14: World Historic Review for Neuroscience by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 15: World 15-Year Perspective for Neuroscience by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2021 & 2027
    • TABLE 16: World Recent Past, Current & Future Analysis for Cytology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 17: World Historic Review for Cytology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 18: World 15-Year Perspective for Cytology by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2021 & 2027
    • TABLE 19: World Recent Past, Current & Future Analysis for Infectious Disease Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 20: World Historic Review for Infectious Disease Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 21: World 15-Year Perspective for Infectious Disease Diagnostics by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2021 & 2027
    • TABLE 22: World Recent Past, Current & Future Analysis for Hospitals & Diagnostic Labs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 23: World Historic Review for Hospitals & Diagnostic Labs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 24: World 15-Year Perspective for Hospitals & Diagnostic Labs by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2021 & 2027
    • TABLE 25: World Recent Past, Current & Future Analysis for Pharma & Biotech Companies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 26: World Historic Review for Pharma & Biotech Companies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 27: World 15-Year Perspective for Pharma & Biotech Companies by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2021 & 2027
    • TABLE 28: World Recent Past, Current & Future Analysis for Contract Research Organizations by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 29: World Historic Review for Contract Research Organizations by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 30: World 15-Year Perspective for Contract Research Organizations by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2021 & 2027
    • TABLE 31: World Recent Past, Current & Future Analysis for Academic & Research Institutions by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 32: World Historic Review for Academic & Research Institutions by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 33: World 15-Year Perspective for Academic & Research Institutions by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2021 & 2027
    • TABLE 34: World Recent Past, Current & Future Analysis for In Situ Hybridization (ISH) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 35: World Historic Review for In Situ Hybridization (ISH) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 36: World 15-Year Perspective for In Situ Hybridization (ISH) by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2012, 2021 & 2027

III. MARKET ANALYSIS

  • UNITED STATES
    • In Situ Hybridization (ISH) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2022 (E)
    • TABLE 37: USA Recent Past, Current & Future Analysis for In Situ Hybridization (ISH) by Technique - Fluorescence In Situ Hybridization (FISH) and Chromogenic In Situ Hybridization (CISH) - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 38: USA Historic Review for In Situ Hybridization (ISH) by Technique - Fluorescence In Situ Hybridization (FISH) and Chromogenic In Situ Hybridization (CISH) Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 39: USA 15-Year Perspective for In Situ Hybridization (ISH) by Technique - Percentage Breakdown of Value Revenues for Fluorescence In Situ Hybridization (FISH) and Chromogenic In Situ Hybridization (CISH) for the Years 2012, 2021 & 2027
    • TABLE 40: USA Recent Past, Current & Future Analysis for In Situ Hybridization (ISH) by Application - Cancer Diagnostics, Immunology, Neuroscience, Cytology and Infectious Disease Diagnostics - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 41: USA Historic Review for In Situ Hybridization (ISH) by Application - Cancer Diagnostics, Immunology, Neuroscience, Cytology and Infectious Disease Diagnostics Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 42: USA 15-Year Perspective for In Situ Hybridization (ISH) by Application - Percentage Breakdown of Value Revenues for Cancer Diagnostics, Immunology, Neuroscience, Cytology and Infectious Disease Diagnostics for the Years 2012, 2021 & 2027
    • TABLE 43: USA Recent Past, Current & Future Analysis for In Situ Hybridization (ISH) by End-Use - Hospitals & Diagnostic Labs, Pharma & Biotech Companies, Contract Research Organizations and Academic & Research Institutions - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 44: USA Historic Review for In Situ Hybridization (ISH) by End-Use - Hospitals & Diagnostic Labs, Pharma & Biotech Companies, Contract Research Organizations and Academic & Research Institutions Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 45: USA 15-Year Perspective for In Situ Hybridization (ISH) by End-Use - Percentage Breakdown of Value Revenues for Hospitals & Diagnostic Labs, Pharma & Biotech Companies, Contract Research Organizations and Academic & Research Institutions for the Years 2012, 2021 & 2027
  • CANADA
    • TABLE 46: Canada Recent Past, Current & Future Analysis for In Situ Hybridization (ISH) by Technique - Fluorescence In Situ Hybridization (FISH) and Chromogenic In Situ Hybridization (CISH) - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 47: Canada Historic Review for In Situ Hybridization (ISH) by Technique - Fluorescence In Situ Hybridization (FISH) and Chromogenic In Situ Hybridization (CISH) Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 48: Canada 15-Year Perspective for In Situ Hybridization (ISH) by Technique - Percentage Breakdown of Value Revenues for Fluorescence In Situ Hybridization (FISH) and Chromogenic In Situ Hybridization (CISH) for the Years 2012, 2021 & 2027
    • TABLE 49: Canada Recent Past, Current & Future Analysis for In Situ Hybridization (ISH) by Application - Cancer Diagnostics, Immunology, Neuroscience, Cytology and Infectious Disease Diagnostics - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 50: Canada Historic Review for In Situ Hybridization (ISH) by Application - Cancer Diagnostics, Immunology, Neuroscience, Cytology and Infectious Disease Diagnostics Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 51: Canada 15-Year Perspective for In Situ Hybridization (ISH) by Application - Percentage Breakdown of Value Revenues for Cancer Diagnostics, Immunology, Neuroscience, Cytology and Infectious Disease Diagnostics for the Years 2012, 2021 & 2027
    • TABLE 52: Canada Recent Past, Current & Future Analysis for In Situ Hybridization (ISH) by End-Use - Hospitals & Diagnostic Labs, Pharma & Biotech Companies, Contract Research Organizations and Academic & Research Institutions - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 53: Canada Historic Review for In Situ Hybridization (ISH) by End-Use - Hospitals & Diagnostic Labs, Pharma & Biotech Companies, Contract Research Organizations and Academic & Research Institutions Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 54: Canada 15-Year Perspective for In Situ Hybridization (ISH) by End-Use - Percentage Breakdown of Value Revenues for Hospitals & Diagnostic Labs, Pharma & Biotech Companies, Contract Research Organizations and Academic & Research Institutions for the Years 2012, 2021 & 2027
  • JAPAN
    • In Situ Hybridization (ISH) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2022 (E)
    • TABLE 55: Japan Recent Past, Current & Future Analysis for In Situ Hybridization (ISH) by Technique - Fluorescence In Situ Hybridization (FISH) and Chromogenic In Situ Hybridization (CISH) - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 56: Japan Historic Review for In Situ Hybridization (ISH) by Technique - Fluorescence In Situ Hybridization (FISH) and Chromogenic In Situ Hybridization (CISH) Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 57: Japan 15-Year Perspective for In Situ Hybridization (ISH) by Technique - Percentage Breakdown of Value Revenues for Fluorescence In Situ Hybridization (FISH) and Chromogenic In Situ Hybridization (CISH) for the Years 2012, 2021 & 2027
    • TABLE 58: Japan Recent Past, Current & Future Analysis for In Situ Hybridization (ISH) by Application - Cancer Diagnostics, Immunology, Neuroscience, Cytology and Infectious Disease Diagnostics - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 59: Japan Historic Review for In Situ Hybridization (ISH) by Application - Cancer Diagnostics, Immunology, Neuroscience, Cytology and Infectious Disease Diagnostics Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 60: Japan 15-Year Perspective for In Situ Hybridization (ISH) by Application - Percentage Breakdown of Value Revenues for Cancer Diagnostics, Immunology, Neuroscience, Cytology and Infectious Disease Diagnostics for the Years 2012, 2021 & 2027
    • TABLE 61: Japan Recent Past, Current & Future Analysis for In Situ Hybridization (ISH) by End-Use - Hospitals & Diagnostic Labs, Pharma & Biotech Companies, Contract Research Organizations and Academic & Research Institutions - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 62: Japan Historic Review for In Situ Hybridization (ISH) by End-Use - Hospitals & Diagnostic Labs, Pharma & Biotech Companies, Contract Research Organizations and Academic & Research Institutions Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 63: Japan 15-Year Perspective for In Situ Hybridization (ISH) by End-Use - Percentage Breakdown of Value Revenues for Hospitals & Diagnostic Labs, Pharma & Biotech Companies, Contract Research Organizations and Academic & Research Institutions for the Years 2012, 2021 & 2027
  • CHINA
    • In Situ Hybridization (ISH) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2022 (E)
    • TABLE 64: China Recent Past, Current & Future Analysis for In Situ Hybridization (ISH) by Technique - Fluorescence In Situ Hybridization (FISH) and Chromogenic In Situ Hybridization (CISH) - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 65: China Historic Review for In Situ Hybridization (ISH) by Technique - Fluorescence In Situ Hybridization (FISH) and Chromogenic In Situ Hybridization (CISH) Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 66: China 15-Year Perspective for In Situ Hybridization (ISH) by Technique - Percentage Breakdown of Value Revenues for Fluorescence In Situ Hybridization (FISH) and Chromogenic In Situ Hybridization (CISH) for the Years 2012, 2021 & 2027
    • TABLE 67: China Recent Past, Current & Future Analysis for In Situ Hybridization (ISH) by Application - Cancer Diagnostics, Immunology, Neuroscience, Cytology and Infectious Disease Diagnostics - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 68: China Historic Review for In Situ Hybridization (ISH) by Application - Cancer Diagnostics, Immunology, Neuroscience, Cytology and Infectious Disease Diagnostics Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 69: China 15-Year Perspective for In Situ Hybridization (ISH) by Application - Percentage Breakdown of Value Revenues for Cancer Diagnostics, Immunology, Neuroscience, Cytology and Infectious Disease Diagnostics for the Years 2012, 2021 & 2027
    • TABLE 70: China Recent Past, Current & Future Analysis for In Situ Hybridization (ISH) by End-Use - Hospitals & Diagnostic Labs, Pharma & Biotech Companies, Contract Research Organizations and Academic & Research Institutions - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 71: China Historic Review for In Situ Hybridization (ISH) by End-Use - Hospitals & Diagnostic Labs, Pharma & Biotech Companies, Contract Research Organizations and Academic & Research Institutions Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 72: China 15-Year Perspective for In Situ Hybridization (ISH) by End-Use - Percentage Breakdown of Value Revenues for Hospitals & Diagnostic Labs, Pharma & Biotech Companies, Contract Research Organizations and Academic & Research Institutions for the Years 2012, 2021 & 2027
  • EUROPE
    • In Situ Hybridization (ISH) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2022 (E)
    • TABLE 73: Europe Recent Past, Current & Future Analysis for In Situ Hybridization (ISH) by Technique - Fluorescence In Situ Hybridization (FISH) and Chromogenic In Situ Hybridization (CISH) - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 74: Europe Historic Review for In Situ Hybridization (ISH) by Technique - Fluorescence In Situ Hybridization (FISH) and Chromogenic In Situ Hybridization (CISH) Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 75: Europe 15-Year Perspective for In Situ Hybridization (ISH) by Technique - Percentage Breakdown of Value Revenues for Fluorescence In Situ Hybridization (FISH) and Chromogenic In Situ Hybridization (CISH) for the Years 2012, 2021 & 2027
    • TABLE 76: Europe Recent Past, Current & Future Analysis for In Situ Hybridization (ISH) by Application - Cancer Diagnostics, Immunology, Neuroscience, Cytology and Infectious Disease Diagnostics - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 77: Europe Historic Review for In Situ Hybridization (ISH) by Application - Cancer Diagnostics, Immunology, Neuroscience, Cytology and Infectious Disease Diagnostics Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 78: Europe 15-Year Perspective for In Situ Hybridization (ISH) by Application - Percentage Breakdown of Value Revenues for Cancer Diagnostics, Immunology, Neuroscience, Cytology and Infectious Disease Diagnostics for the Years 2012, 2021 & 2027
    • TABLE 79: Europe Recent Past, Current & Future Analysis for In Situ Hybridization (ISH) by End-Use - Hospitals & Diagnostic Labs, Pharma & Biotech Companies, Contract Research Organizations and Academic & Research Institutions - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 80: Europe Historic Review for In Situ Hybridization (ISH) by End-Use - Hospitals & Diagnostic Labs, Pharma & Biotech Companies, Contract Research Organizations and Academic & Research Institutions Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 81: Europe 15-Year Perspective for In Situ Hybridization (ISH) by End-Use - Percentage Breakdown of Value Revenues for Hospitals & Diagnostic Labs, Pharma & Biotech Companies, Contract Research Organizations and Academic & Research Institutions for the Years 2012, 2021 & 2027
    • TABLE 82: Europe Recent Past, Current & Future Analysis for In Situ Hybridization (ISH) by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 83: Europe Historic Review for In Situ Hybridization (ISH) by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 84: Europe 15-Year Perspective for In Situ Hybridization (ISH) by Geographic Region - Percentage Breakdown of Value Revenues for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2012, 2021 & 2027
  • FRANCE
    • In Situ Hybridization (ISH) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2022 (E)
    • TABLE 85: France Recent Past, Current & Future Analysis for In Situ Hybridization (ISH) by Technique - Fluorescence In Situ Hybridization (FISH) and Chromogenic In Situ Hybridization (CISH) - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 86: France Historic Review for In Situ Hybridization (ISH) by Technique - Fluorescence In Situ Hybridization (FISH) and Chromogenic In Situ Hybridization (CISH) Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 87: France 15-Year Perspective for In Situ Hybridization (ISH) by Technique - Percentage Breakdown of Value Revenues for Fluorescence In Situ Hybridization (FISH) and Chromogenic In Situ Hybridization (CISH) for the Years 2012, 2021 & 2027
    • TABLE 88: France Recent Past, Current & Future Analysis for In Situ Hybridization (ISH) by Application - Cancer Diagnostics, Immunology, Neuroscience, Cytology and Infectious Disease Diagnostics - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 89: France Historic Review for In Situ Hybridization (ISH) by Application - Cancer Diagnostics, Immunology, Neuroscience, Cytology and Infectious Disease Diagnostics Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 90: France 15-Year Perspective for In Situ Hybridization (ISH) by Application - Percentage Breakdown of Value Revenues for Cancer Diagnostics, Immunology, Neuroscience, Cytology and Infectious Disease Diagnostics for the Years 2012, 2021 & 2027
    • TABLE 91: France Recent Past, Current & Future Analysis for In Situ Hybridization (ISH) by End-Use - Hospitals & Diagnostic Labs, Pharma & Biotech Companies, Contract Research Organizations and Academic & Research Institutions - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 92: France Historic Review for In Situ Hybridization (ISH) by End-Use - Hospitals & Diagnostic Labs, Pharma & Biotech Companies, Contract Research Organizations and Academic & Research Institutions Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 93: France 15-Year Perspective for In Situ Hybridization (ISH) by End-Use - Percentage Breakdown of Value Revenues for Hospitals & Diagnostic Labs, Pharma & Biotech Companies, Contract Research Organizations and Academic & Research Institutions for the Years 2012, 2021 & 2027
  • GERMANY
    • In Situ Hybridization (ISH) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2022 (E)
    • TABLE 94: Germany Recent Past, Current & Future Analysis for In Situ Hybridization (ISH) by Technique - Fluorescence In Situ Hybridization (FISH) and Chromogenic In Situ Hybridization (CISH) - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 95: Germany Historic Review for In Situ Hybridization (ISH) by Technique - Fluorescence In Situ Hybridization (FISH) and Chromogenic In Situ Hybridization (CISH) Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 96: Germany 15-Year Perspective for In Situ Hybridization (ISH) by Technique - Percentage Breakdown of Value Revenues for Fluorescence In Situ Hybridization (FISH) and Chromogenic In Situ Hybridization (CISH) for the Years 2012, 2021 & 2027
    • TABLE 97: Germany Recent Past, Current & Future Analysis for In Situ Hybridization (ISH) by Application - Cancer Diagnostics, Immunology, Neuroscience, Cytology and Infectious Disease Diagnostics - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 98: Germany Historic Review for In Situ Hybridization (ISH) by Application - Cancer Diagnostics, Immunology, Neuroscience, Cytology and Infectious Disease Diagnostics Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 99: Germany 15-Year Perspective for In Situ Hybridization (ISH) by Application - Percentage Breakdown of Value Revenues for Cancer Diagnostics, Immunology, Neuroscience, Cytology and Infectious Disease Diagnostics for the Years 2012, 2021 & 2027
    • TABLE 100: Germany Recent Past, Current & Future Analysis for In Situ Hybridization (ISH) by End-Use - Hospitals & Diagnostic Labs, Pharma & Biotech Companies, Contract Research Organizations and Academic & Research Institutions - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 101: Germany Historic Review for In Situ Hybridization (ISH) by End-Use - Hospitals & Diagnostic Labs, Pharma & Biotech Companies, Contract Research Organizations and Academic & Research Institutions Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 102: Germany 15-Year Perspective for In Situ Hybridization (ISH) by End-Use - Percentage Breakdown of Value Revenues for Hospitals & Diagnostic Labs, Pharma & Biotech Companies, Contract Research Organizations and Academic & Research Institutions for the Years 2012, 2021 & 2027
  • ITALY
    • TABLE 103: Italy Recent Past, Current & Future Analysis for In Situ Hybridization (ISH) by Technique - Fluorescence In Situ Hybridization (FISH) and Chromogenic In Situ Hybridization (CISH) - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 104: Italy Historic Review for In Situ Hybridization (ISH) by Technique - Fluorescence In Situ Hybridization (FISH) and Chromogenic In Situ Hybridization (CISH) Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 105: Italy 15-Year Perspective for In Situ Hybridization (ISH) by Technique - Percentage Breakdown of Value Revenues for Fluorescence In Situ Hybridization (FISH) and Chromogenic In Situ Hybridization (CISH) for the Years 2012, 2021 & 2027
    • TABLE 106: Italy Recent Past, Current & Future Analysis for In Situ Hybridization (ISH) by Application - Cancer Diagnostics, Immunology, Neuroscience, Cytology and Infectious Disease Diagnostics - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 107: Italy Historic Review for In Situ Hybridization (ISH) by Application - Cancer Diagnostics, Immunology, Neuroscience, Cytology and Infectious Disease Diagnostics Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 108: Italy 15-Year Perspective for In Situ Hybridization (ISH) by Application - Percentage Breakdown of Value Revenues for Cancer Diagnostics, Immunology, Neuroscience, Cytology and Infectious Disease Diagnostics for the Years 2012, 2021 & 2027
    • TABLE 109: Italy Recent Past, Current & Future Analysis for In Situ Hybridization (ISH) by End-Use - Hospitals & Diagnostic Labs, Pharma & Biotech Companies, Contract Research Organizations and Academic & Research Institutions - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 110: Italy Historic Review for In Situ Hybridization (ISH) by End-Use - Hospitals & Diagnostic Labs, Pharma & Biotech Companies, Contract Research Organizations and Academic & Research Institutions Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 111: Italy 15-Year Perspective for In Situ Hybridization (ISH) by End-Use - Percentage Breakdown of Value Revenues for Hospitals & Diagnostic Labs, Pharma & Biotech Companies, Contract Research Organizations and Academic & Research Institutions for the Years 2012, 2021 & 2027
  • UNITED KINGDOM
    • In Situ Hybridization (ISH) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2022 (E)
    • TABLE 112: UK Recent Past, Current & Future Analysis for In Situ Hybridization (ISH) by Technique - Fluorescence In Situ Hybridization (FISH) and Chromogenic In Situ Hybridization (CISH) - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 113: UK Historic Review for In Situ Hybridization (ISH) by Technique - Fluorescence In Situ Hybridization (FISH) and Chromogenic In Situ Hybridization (CISH) Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 114: UK 15-Year Perspective for In Situ Hybridization (ISH) by Technique - Percentage Breakdown of Value Revenues for Fluorescence In Situ Hybridization (FISH) and Chromogenic In Situ Hybridization (CISH) for the Years 2012, 2021 & 2027
    • TABLE 115: UK Recent Past, Current & Future Analysis for In Situ Hybridization (ISH) by Application - Cancer Diagnostics, Immunology, Neuroscience, Cytology and Infectious Disease Diagnostics - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 116: UK Historic Review for In Situ Hybridization (ISH) by Application - Cancer Diagnostics, Immunology, Neuroscience, Cytology and Infectious Disease Diagnostics Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 117: UK 15-Year Perspective for In Situ Hybridization (ISH) by Application - Percentage Breakdown of Value Revenues for Cancer Diagnostics, Immunology, Neuroscience, Cytology and Infectious Disease Diagnostics for the Years 2012, 2021 & 2027
    • TABLE 118: UK Recent Past, Current & Future Analysis for In Situ Hybridization (ISH) by End-Use - Hospitals & Diagnostic Labs, Pharma & Biotech Companies, Contract Research Organizations and Academic & Research Institutions - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 119: UK Historic Review for In Situ Hybridization (ISH) by End-Use - Hospitals & Diagnostic Labs, Pharma & Biotech Companies, Contract Research Organizations and Academic & Research Institutions Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 120: UK 15-Year Perspective for In Situ Hybridization (ISH) by End-Use - Percentage Breakdown of Value Revenues for Hospitals & Diagnostic Labs, Pharma & Biotech Companies, Contract Research Organizations and Academic & Research Institutions for the Years 2012, 2021 & 2027
  • SPAIN
    • TABLE 121: Spain Recent Past, Current & Future Analysis for In Situ Hybridization (ISH) by Technique - Fluorescence In Situ Hybridization (FISH) and Chromogenic In Situ Hybridization (CISH) - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 122: Spain Historic Review for In Situ Hybridization (ISH) by Technique - Fluorescence In Situ Hybridization (FISH) and Chromogenic In Situ Hybridization (CISH) Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 123: Spain 15-Year Perspective for In Situ Hybridization (ISH) by Technique - Percentage Breakdown of Value Revenues for Fluorescence In Situ Hybridization (FISH) and Chromogenic In Situ Hybridization (CISH) for the Years 2012, 2021 & 2027
    • TABLE 124: Spain Recent Past, Current & Future Analysis for In Situ Hybridization (ISH) by Application - Cancer Diagnostics, Immunology, Neuroscience, Cytology and Infectious Disease Diagnostics - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 125: Spain Historic Review for In Situ Hybridization (ISH) by Application - Cancer Diagnostics, Immunology, Neuroscience, Cytology and Infectious Disease Diagnostics Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 126: Spain 15-Year Perspective for In Situ Hybridization (ISH) by Application - Percentage Breakdown of Value Revenues for Cancer Diagnostics, Immunology, Neuroscience, Cytology and Infectious Disease Diagnostics for the Years 2012, 2021 & 2027
    • TABLE 127: Spain Recent Past, Current & Future Analysis for In Situ Hybridization (ISH) by End-Use - Hospitals & Diagnostic Labs, Pharma & Biotech Companies, Contract Research Organizations and Academic & Research Institutions - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 128: Spain Historic Review for In Situ Hybridization (ISH) by End-Use - Hospitals & Diagnostic Labs, Pharma & Biotech Companies, Contract Research Organizations and Academic & Research Institutions Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 129: Spain 15-Year Perspective for In Situ Hybridization (ISH) by End-Use - Percentage Breakdown of Value Revenues for Hospitals & Diagnostic Labs, Pharma & Biotech Companies, Contract Research Organizations and Academic & Research Institutions for the Years 2012, 2021 & 2027
  • RUSSIA
    • TABLE 130: Russia Recent Past, Current & Future Analysis for In Situ Hybridization (ISH) by Technique - Fluorescence In Situ Hybridization (FISH) and Chromogenic In Situ Hybridization (CISH) - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 131: Russia Historic Review for In Situ Hybridization (ISH) by Technique - Fluorescence In Situ Hybridization (FISH) and Chromogenic In Situ Hybridization (CISH) Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 132: Russia 15-Year Perspective for In Situ Hybridization (ISH) by Technique - Percentage Breakdown of Value Revenues for Fluorescence In Situ Hybridization (FISH) and Chromogenic In Situ Hybridization (CISH) for the Years 2012, 2021 & 2027
    • TABLE 133: Russia Recent Past, Current & Future Analysis for In Situ Hybridization (ISH) by Application - Cancer Diagnostics, Immunology, Neuroscience, Cytology and Infectious Disease Diagnostics - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 134: Russia Historic Review for In Situ Hybridization (ISH) by Application - Cancer Diagnostics, Immunology, Neuroscience, Cytology and Infectious Disease Diagnostics Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 135: Russia 15-Year Perspective for In Situ Hybridization (ISH) by Application - Percentage Breakdown of Value Revenues for Cancer Diagnostics, Immunology, Neuroscience, Cytology and Infectious Disease Diagnostics for the Years 2012, 2021 & 2027
    • TABLE 136: Russia Recent Past, Current & Future Analysis for In Situ Hybridization (ISH) by End-Use - Hospitals & Diagnostic Labs, Pharma & Biotech Companies, Contract Research Organizations and Academic & Research Institutions - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 137: Russia Historic Review for In Situ Hybridization (ISH) by End-Use - Hospitals & Diagnostic Labs, Pharma & Biotech Companies, Contract Research Organizations and Academic & Research Institutions Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 138: Russia 15-Year Perspective for In Situ Hybridization (ISH) by End-Use - Percentage Breakdown of Value Revenues for Hospitals & Diagnostic Labs, Pharma & Biotech Companies, Contract Research Organizations and Academic & Research Institutions for the Years 2012, 2021 & 2027
  • REST OF EUROPE
    • TABLE 139: Rest of Europe Recent Past, Current & Future Analysis for In Situ Hybridization (ISH) by Technique - Fluorescence In Situ Hybridization (FISH) and Chromogenic In Situ Hybridization (CISH) - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 140: Rest of Europe Historic Review for In Situ Hybridization (ISH) by Technique - Fluorescence In Situ Hybridization (FISH) and Chromogenic In Situ Hybridization (CISH) Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 141: Rest of Europe 15-Year Perspective for In Situ Hybridization (ISH) by Technique - Percentage Breakdown of Value Revenues for Fluorescence In Situ Hybridization (FISH) and Chromogenic In Situ Hybridization (CISH) for the Years 2012, 2021 & 2027
    • TABLE 142: Rest of Europe Recent Past, Current & Future Analysis for In Situ Hybridization (ISH) by Application - Cancer Diagnostics, Immunology, Neuroscience, Cytology and Infectious Disease Diagnostics - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 143: Rest of Europe Historic Review for In Situ Hybridization (ISH) by Application - Cancer Diagnostics, Immunology, Neuroscience, Cytology and Infectious Disease Diagnostics Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 144: Rest of Europe 15-Year Perspective for In Situ Hybridization (ISH) by Application - Percentage Breakdown of Value Revenues for Cancer Diagnostics, Immunology, Neuroscience, Cytology and Infectious Disease Diagnostics for the Years 2012, 2021 & 2027
    • TABLE 145: Rest of Europe Recent Past, Current & Future Analysis for In Situ Hybridization (ISH) by End-Use - Hospitals & Diagnostic Labs, Pharma & Biotech Companies, Contract Research Organizations and Academic & Research Institutions - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 146: Rest of Europe Historic Review for In Situ Hybridization (ISH) by End-Use - Hospitals & Diagnostic Labs, Pharma & Biotech Companies, Contract Research Organizations and Academic & Research Institutions Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 147: Rest of Europe 15-Year Perspective for In Situ Hybridization (ISH) by End-Use - Percentage Breakdown of Value Revenues for Hospitals & Diagnostic Labs, Pharma & Biotech Companies, Contract Research Organizations and Academic & Research Institutions for the Years 2012, 2021 & 2027
  • ASIA-PACIFIC
    • In Situ Hybridization (ISH) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2022 (E)
    • TABLE 148: Asia-Pacific Recent Past, Current & Future Analysis for In Situ Hybridization (ISH) by Technique - Fluorescence In Situ Hybridization (FISH) and Chromogenic In Situ Hybridization (CISH) - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 149: Asia-Pacific Historic Review for In Situ Hybridization (ISH) by Technique - Fluorescence In Situ Hybridization (FISH) and Chromogenic In Situ Hybridization (CISH) Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 150: Asia-Pacific 15-Year Perspective for In Situ Hybridization (ISH) by Technique - Percentage Breakdown of Value Revenues for Fluorescence In Situ Hybridization (FISH) and Chromogenic In Situ Hybridization (CISH) for the Years 2012, 2021 & 2027
    • TABLE 151: Asia-Pacific Recent Past, Current & Future Analysis for In Situ Hybridization (ISH) by Application - Cancer Diagnostics, Immunology, Neuroscience, Cytology and Infectious Disease Diagnostics - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 152: Asia-Pacific Historic Review for In Situ Hybridization (ISH) by Application - Cancer Diagnostics, Immunology, Neuroscience, Cytology and Infectious Disease Diagnostics Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 153: Asia-Pacific 15-Year Perspective for In Situ Hybridization (ISH) by Application - Percentage Breakdown of Value Revenues for Cancer Diagnostics, Immunology, Neuroscience, Cytology and Infectious Disease Diagnostics for the Years 2012, 2021 & 2027
    • TABLE 154: Asia-Pacific Recent Past, Current & Future Analysis for In Situ Hybridization (ISH) by End-Use - Hospitals & Diagnostic Labs, Pharma & Biotech Companies, Contract Research Organizations and Academic & Research Institutions - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 155: Asia-Pacific Historic Review for In Situ Hybridization (ISH) by End-Use - Hospitals & Diagnostic Labs, Pharma & Biotech Companies, Contract Research Organizations and Academic & Research Institutions Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 156: Asia-Pacific 15-Year Perspective for In Situ Hybridization (ISH) by End-Use - Percentage Breakdown of Value Revenues for Hospitals & Diagnostic Labs, Pharma & Biotech Companies, Contract Research Organizations and Academic & Research Institutions for the Years 2012, 2021 & 2027
    • TABLE 157: Asia-Pacific Recent Past, Current & Future Analysis for In Situ Hybridization (ISH) by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 158: Asia-Pacific Historic Review for In Situ Hybridization (ISH) by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 159: Asia-Pacific 15-Year Perspective for In Situ Hybridization (ISH) by Geographic Region - Percentage Breakdown of Value Revenues for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2012, 2021 & 2027
  • AUSTRALIA
    • In Situ Hybridization (ISH) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2022 (E)
    • TABLE 160: Australia Recent Past, Current & Future Analysis for In Situ Hybridization (ISH) by Technique - Fluorescence In Situ Hybridization (FISH) and Chromogenic In Situ Hybridization (CISH) - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 161: Australia Historic Review for In Situ Hybridization (ISH) by Technique - Fluorescence In Situ Hybridization (FISH) and Chromogenic In Situ Hybridization (CISH) Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 162: Australia 15-Year Perspective for In Situ Hybridization (ISH) by Technique - Percentage Breakdown of Value Revenues for Fluorescence In Situ Hybridization (FISH) and Chromogenic In Situ Hybridization (CISH) for the Years 2012, 2021 & 2027
    • TABLE 163: Australia Recent Past, Current & Future Analysis for In Situ Hybridization (ISH) by Application - Cancer Diagnostics, Immunology, Neuroscience, Cytology and Infectious Disease Diagnostics - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 164: Australia Historic Review for In Situ Hybridization (ISH) by Application - Cancer Diagnostics, Immunology, Neuroscience, Cytology and Infectious Disease Diagnostics Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 165: Australia 15-Year Perspective for In Situ Hybridization (ISH) by Application - Percentage Breakdown of Value Revenues for Cancer Diagnostics, Immunology, Neuroscience, Cytology and Infectious Disease Diagnostics for the Years 2012, 2021 & 2027
    • TABLE 166: Australia Recent Past, Current & Future Analysis for In Situ Hybridization (ISH) by End-Use - Hospitals & Diagnostic Labs, Pharma & Biotech Companies, Contract Research Organizations and Academic & Research Institutions - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 167: Australia Historic Review for In Situ Hybridization (ISH) by End-Use - Hospitals & Diagnostic Labs, Pharma & Biotech Companies, Contract Research Organizations and Academic & Research Institutions Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 168: Australia 15-Year Perspective for In Situ Hybridization (ISH) by End-Use - Percentage Breakdown of Value Revenues for Hospitals & Diagnostic Labs, Pharma & Biotech Companies, Contract Research Organizations and Academic & Research Institutions for the Years 2012, 2021 & 2027
  • INDIA
    • In Situ Hybridization (ISH) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2022 (E)
    • TABLE 169: India Recent Past, Current & Future Analysis for In Situ Hybridization (ISH) by Technique - Fluorescence In Situ Hybridization (FISH) and Chromogenic In Situ Hybridization (CISH) - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 170: India Historic Review for In Situ Hybridization (ISH) by Technique - Fluorescence In Situ Hybridization (FISH) and Chromogenic In Situ Hybridization (CISH) Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 171: India 15-Year Perspective for In Situ Hybridization (ISH) by Technique - Percentage Breakdown of Value Revenues for Fluorescence In Situ Hybridization (FISH) and Chromogenic In Situ Hybridization (CISH) for the Years 2012, 2021 & 2027
    • TABLE 172: India Recent Past, Current & Future Analysis for In Situ Hybridization (ISH) by Application - Cancer Diagnostics, Immunology, Neuroscience, Cytology and Infectious Disease Diagnostics - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 173: India Historic Review for In Situ Hybridization (ISH) by Application - Cancer Diagnostics, Immunology, Neuroscience, Cytology and Infectious Disease Diagnostics Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 174: India 15-Year Perspective for In Situ Hybridization (ISH) by Application - Percentage Breakdown of Value Revenues for Cancer Diagnostics, Immunology, Neuroscience, Cytology and Infectious Disease Diagnostics for the Years 2012, 2021 & 2027
    • TABLE 175: India Recent Past, Current & Future Analysis for In Situ Hybridization (ISH) by End-Use - Hospitals & Diagnostic Labs, Pharma & Biotech Companies, Contract Research Organizations and Academic & Research Institutions - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 176: India Historic Review for In Situ Hybridization (ISH) by End-Use - Hospitals & Diagnostic Labs, Pharma & Biotech Companies, Contract Research Organizations and Academic & Research Institutions Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 177: India 15-Year Perspective for In Situ Hybridization (ISH) by End-Use - Percentage Breakdown of Value Revenues for Hospitals & Diagnostic Labs, Pharma & Biotech Companies, Contract Research Organizations and Academic & Research Institutions for the Years 2012, 2021 & 2027
  • SOUTH KOREA
    • TABLE 178: South Korea Recent Past, Current & Future Analysis for In Situ Hybridization (ISH) by Technique - Fluorescence In Situ Hybridization (FISH) and Chromogenic In Situ Hybridization (CISH) - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 179: South Korea Historic Review for In Situ Hybridization (ISH) by Technique - Fluorescence In Situ Hybridization (FISH) and Chromogenic In Situ Hybridization (CISH) Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 180: South Korea 15-Year Perspective for In Situ Hybridization (ISH) by Technique - Percentage Breakdown of Value Revenues for Fluorescence In Situ Hybridization (FISH) and Chromogenic In Situ Hybridization (CISH) for the Years 2012, 2021 & 2027
    • TABLE 181: South Korea Recent Past, Current & Future Analysis for In Situ Hybridization (ISH) by Application - Cancer Diagnostics, Immunology, Neuroscience, Cytology and Infectious Disease Diagnostics - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 182: South Korea Historic Review for In Situ Hybridization (ISH) by Application - Cancer Diagnostics, Immunology, Neuroscience, Cytology and Infectious Disease Diagnostics Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 183: South Korea 15-Year Perspective for In Situ Hybridization (ISH) by Application - Percentage Breakdown of Value Revenues for Cancer Diagnostics, Immunology, Neuroscience, Cytology and Infectious Disease Diagnostics for the Years 2012, 2021 & 2027
    • TABLE 184: South Korea Recent Past, Current & Future Analysis for In Situ Hybridization (ISH) by End-Use - Hospitals & Diagnostic Labs, Pharma & Biotech Companies, Contract Research Organizations and Academic & Research Institutions - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 185: South Korea Historic Review for In Situ Hybridization (ISH) by End-Use - Hospitals & Diagnostic Labs, Pharma & Biotech Companies, Contract Research Organizations and Academic & Research Institutions Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 186: South Korea 15-Year Perspective for In Situ Hybridization (ISH) by End-Use - Percentage Breakdown of Value Revenues for Hospitals & Diagnostic Labs, Pharma & Biotech Companies, Contract Research Organizations and Academic & Research Institutions for the Years 2012, 2021 & 2027
  • REST OF ASIA-PACIFIC
    • TABLE 187: Rest of Asia-Pacific Recent Past, Current & Future Analysis for In Situ Hybridization (ISH) by Technique - Fluorescence In Situ Hybridization (FISH) and Chromogenic In Situ Hybridization (CISH) - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 188: Rest of Asia-Pacific Historic Review for In Situ Hybridization (ISH) by Technique - Fluorescence In Situ Hybridization (FISH) and Chromogenic In Situ Hybridization (CISH) Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 189: Rest of Asia-Pacific 15-Year Perspective for In Situ Hybridization (ISH) by Technique - Percentage Breakdown of Value Revenues for Fluorescence In Situ Hybridization (FISH) and Chromogenic In Situ Hybridization (CISH) for the Years 2012, 2021 & 2027
    • TABLE 190: Rest of Asia-Pacific Recent Past, Current & Future Analysis for In Situ Hybridization (ISH) by Application - Cancer Diagnostics, Immunology, Neuroscience, Cytology and Infectious Disease Diagnostics - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 191: Rest of Asia-Pacific Historic Review for In Situ Hybridization (ISH) by Application - Cancer Diagnostics, Immunology, Neuroscience, Cytology and Infectious Disease Diagnostics Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 192: Rest of Asia-Pacific 15-Year Perspective for In Situ Hybridization (ISH) by Application - Percentage Breakdown of Value Revenues for Cancer Diagnostics, Immunology, Neuroscience, Cytology and Infectious Disease Diagnostics for the Years 2012, 2021 & 2027
    • TABLE 193: Rest of Asia-Pacific Recent Past, Current & Future Analysis for In Situ Hybridization (ISH) by End-Use - Hospitals & Diagnostic Labs, Pharma & Biotech Companies, Contract Research Organizations and Academic & Research Institutions - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 194: Rest of Asia-Pacific Historic Review for In Situ Hybridization (ISH) by End-Use - Hospitals & Diagnostic Labs, Pharma & Biotech Companies, Contract Research Organizations and Academic & Research Institutions Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 195: Rest of Asia-Pacific 15-Year Perspective for In Situ Hybridization (ISH) by End-Use - Percentage Breakdown of Value Revenues for Hospitals & Diagnostic Labs, Pharma & Biotech Companies, Contract Research Organizations and Academic & Research Institutions for the Years 2012, 2021 & 2027
  • LATIN AMERICA
    • In Situ Hybridization (ISH) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2022 (E)
    • TABLE 196: Latin America Recent Past, Current & Future Analysis for In Situ Hybridization (ISH) by Technique - Fluorescence In Situ Hybridization (FISH) and Chromogenic In Situ Hybridization (CISH) - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 197: Latin America Historic Review for In Situ Hybridization (ISH) by Technique - Fluorescence In Situ Hybridization (FISH) and Chromogenic In Situ Hybridization (CISH) Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 198: Latin America 15-Year Perspective for In Situ Hybridization (ISH) by Technique - Percentage Breakdown of Value Revenues for Fluorescence In Situ Hybridization (FISH) and Chromogenic In Situ Hybridization (CISH) for the Years 2012, 2021 & 2027
    • TABLE 199: Latin America Recent Past, Current & Future Analysis for In Situ Hybridization (ISH) by Application - Cancer Diagnostics, Immunology, Neuroscience, Cytology and Infectious Disease Diagnostics - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 200: Latin America Historic Review for In Situ Hybridization (ISH) by Application - Cancer Diagnostics, Immunology, Neuroscience, Cytology and Infectious Disease Diagnostics Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 201: Latin America 15-Year Perspective for In Situ Hybridization (ISH) by Application - Percentage Breakdown of Value Revenues for Cancer Diagnostics, Immunology, Neuroscience, Cytology and Infectious Disease Diagnostics for the Years 2012, 2021 & 2027
    • TABLE 202: Latin America Recent Past, Current & Future Analysis for In Situ Hybridization (ISH) by End-Use - Hospitals & Diagnostic Labs, Pharma & Biotech Companies, Contract Research Organizations and Academic & Research Institutions - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 203: Latin America Historic Review for In Situ Hybridization (ISH) by End-Use - Hospitals & Diagnostic Labs, Pharma & Biotech Companies, Contract Research Organizations and Academic & Research Institutions Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 204: Latin America 15-Year Perspective for In Situ Hybridization (ISH) by End-Use - Percentage Breakdown of Value Revenues for Hospitals & Diagnostic Labs, Pharma & Biotech Companies, Contract Research Organizations and Academic & Research Institutions for the Years 2012, 2021 & 2027
    • TABLE 205: Latin America Recent Past, Current & Future Analysis for In Situ Hybridization (ISH) by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 206: Latin America Historic Review for In Situ Hybridization (ISH) by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 207: Latin America 15-Year Perspective for In Situ Hybridization (ISH) by Geographic Region - Percentage Breakdown of Value Revenues for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2012, 2021 & 2027
  • ARGENTINA
    • TABLE 208: Argentina Recent Past, Current & Future Analysis for In Situ Hybridization (ISH) by Technique - Fluorescence In Situ Hybridization (FISH) and Chromogenic In Situ Hybridization (CISH) - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 209: Argentina Historic Review for In Situ Hybridization (ISH) by Technique - Fluorescence In Situ Hybridization (FISH) and Chromogenic In Situ Hybridization (CISH) Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 210: Argentina 15-Year Perspective for In Situ Hybridization (ISH) by Technique - Percentage Breakdown of Value Revenues for Fluorescence In Situ Hybridization (FISH) and Chromogenic In Situ Hybridization (CISH) for the Years 2012, 2021 & 2027
    • TABLE 211: Argentina Recent Past, Current & Future Analysis for In Situ Hybridization (ISH) by Application - Cancer Diagnostics, Immunology, Neuroscience, Cytology and Infectious Disease Diagnostics - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 212: Argentina Historic Review for In Situ Hybridization (ISH) by Application - Cancer Diagnostics, Immunology, Neuroscience, Cytology and Infectious Disease Diagnostics Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 213: Argentina 15-Year Perspective for In Situ Hybridization (ISH) by Application - Percentage Breakdown of Value Revenues for Cancer Diagnostics, Immunology, Neuroscience, Cytology and Infectious Disease Diagnostics for the Years 2012, 2021 & 2027
    • TABLE 214: Argentina Recent Past, Current & Future Analysis for In Situ Hybridization (ISH) by End-Use - Hospitals & Diagnostic Labs, Pharma & Biotech Companies, Contract Research Organizations and Academic & Research Institutions - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 215: Argentina Historic Review for In Situ Hybridization (ISH) by End-Use - Hospitals & Diagnostic Labs, Pharma & Biotech Companies, Contract Research Organizations and Academic & Research Institutions Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 216: Argentina 15-Year Perspective for In Situ Hybridization (ISH) by End-Use - Percentage Breakdown of Value Revenues for Hospitals & Diagnostic Labs, Pharma & Biotech Companies, Contract Research Organizations and Academic & Research Institutions for the Years 2012, 2021 & 2027
  • BRAZIL
    • TABLE 217: Brazil Recent Past, Current & Future Analysis for In Situ Hybridization (ISH) by Technique - Fluorescence In Situ Hybridization (FISH) and Chromogenic In Situ Hybridization (CISH) - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 218: Brazil Historic Review for In Situ Hybridization (ISH) by Technique - Fluorescence In Situ Hybridization (FISH) and Chromogenic In Situ Hybridization (CISH) Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 219: Brazil 15-Year Perspective for In Situ Hybridization (ISH) by Technique - Percentage Breakdown of Value Revenues for Fluorescence In Situ Hybridization (FISH) and Chromogenic In Situ Hybridization (CISH) for the Years 2012, 2021 & 2027
    • TABLE 220: Brazil Recent Past, Current & Future Analysis for In Situ Hybridization (ISH) by Application - Cancer Diagnostics, Immunology, Neuroscience, Cytology and Infectious Disease Diagnostics - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 221: Brazil Historic Review for In Situ Hybridization (ISH) by Application - Cancer Diagnostics, Immunology, Neuroscience, Cytology and Infectious Disease Diagnostics Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 222: Brazil 15-Year Perspective for In Situ Hybridization (ISH) by Application - Percentage Breakdown of Value Revenues for Cancer Diagnostics, Immunology, Neuroscience, Cytology and Infectious Disease Diagnostics for the Years 2012, 2021 & 2027
    • TABLE 223: Brazil Recent Past, Current & Future Analysis for In Situ Hybridization (ISH) by End-Use - Hospitals & Diagnostic Labs, Pharma & Biotech Companies, Contract Research Organizations and Academic & Research Institutions - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 224: Brazil Historic Review for In Situ Hybridization (ISH) by End-Use - Hospitals & Diagnostic Labs, Pharma & Biotech Companies, Contract Research Organizations and Academic & Research Institutions Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 225: Brazil 15-Year Perspective for In Situ Hybridization (ISH) by End-Use - Percentage Breakdown of Value Revenues for Hospitals & Diagnostic Labs, Pharma & Biotech Companies, Contract Research Organizations and Academic & Research Institutions for the Years 2012, 2021 & 2027
  • MEXICO
    • TABLE 226: Mexico Recent Past, Current & Future Analysis for In Situ Hybridization (ISH) by Technique - Fluorescence In Situ Hybridization (FISH) and Chromogenic In Situ Hybridization (CISH) - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 227: Mexico Historic Review for In Situ Hybridization (ISH) by Technique - Fluorescence In Situ Hybridization (FISH) and Chromogenic In Situ Hybridization (CISH) Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 228: Mexico 15-Year Perspective for In Situ Hybridization (ISH) by Technique - Percentage Breakdown of Value Revenues for Fluorescence In Situ Hybridization (FISH) and Chromogenic In Situ Hybridization (CISH) for the Years 2012, 2021 & 2027
    • TABLE 229: Mexico Recent Past, Current & Future Analysis for In Situ Hybridization (ISH) by Application - Cancer Diagnostics, Immunology, Neuroscience, Cytology and Infectious Disease Diagnostics - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 230: Mexico Historic Review for In Situ Hybridization (ISH) by Application - Cancer Diagnostics, Immunology, Neuroscience, Cytology and Infectious Disease Diagnostics Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 231: Mexico 15-Year Perspective for In Situ Hybridization (ISH) by Application - Percentage Breakdown of Value Revenues for Cancer Diagnostics, Immunology, Neuroscience, Cytology and Infectious Disease Diagnostics for the Years 2012, 2021 & 2027
    • TABLE 232: Mexico Recent Past, Current & Future Analysis for In Situ Hybridization (ISH) by End-Use - Hospitals & Diagnostic Labs, Pharma & Biotech Companies, Contract Research Organizations and Academic & Research Institutions - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 233: Mexico Historic Review for In Situ Hybridization (ISH) by End-Use - Hospitals & Diagnostic Labs, Pharma & Biotech Companies, Contract Research Organizations and Academic & Research Institutions Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 234: Mexico 15-Year Perspective for In Situ Hybridization (ISH) by End-Use - Percentage Breakdown of Value Revenues for Hospitals & Diagnostic Labs, Pharma & Biotech Companies, Contract Research Organizations and Academic & Research Institutions for the Years 2012, 2021 & 2027
  • REST OF LATIN AMERICA
    • TABLE 235: Rest of Latin America Recent Past, Current & Future Analysis for In Situ Hybridization (ISH) by Technique - Fluorescence In Situ Hybridization (FISH) and Chromogenic In Situ Hybridization (CISH) - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 236: Rest of Latin America Historic Review for In Situ Hybridization (ISH) by Technique - Fluorescence In Situ Hybridization (FISH) and Chromogenic In Situ Hybridization (CISH) Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 237: Rest of Latin America 15-Year Perspective for In Situ Hybridization (ISH) by Technique - Percentage Breakdown of Value Revenues for Fluorescence In Situ Hybridization (FISH) and Chromogenic In Situ Hybridization (CISH) for the Years 2012, 2021 & 2027
    • TABLE 238: Rest of Latin America Recent Past, Current & Future Analysis for In Situ Hybridization (ISH) by Application - Cancer Diagnostics, Immunology, Neuroscience, Cytology and Infectious Disease Diagnostics - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 239: Rest of Latin America Historic Review for In Situ Hybridization (ISH) by Application - Cancer Diagnostics, Immunology, Neuroscience, Cytology and Infectious Disease Diagnostics Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 240: Rest of Latin America 15-Year Perspective for In Situ Hybridization (ISH) by Application - Percentage Breakdown of Value Revenues for Cancer Diagnostics, Immunology, Neuroscience, Cytology and Infectious Disease Diagnostics for the Years 2012, 2021 & 2027
    • TABLE 241: Rest of Latin America Recent Past, Current & Future Analysis for In Situ Hybridization (ISH) by End-Use - Hospitals & Diagnostic Labs, Pharma & Biotech Companies, Contract Research Organizations and Academic & Research Institutions - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 242: Rest of Latin America Historic Review for In Situ Hybridization (ISH) by End-Use - Hospitals & Diagnostic Labs, Pharma & Biotech Companies, Contract Research Organizations and Academic & Research Institutions Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 243: Rest of Latin America 15-Year Perspective for In Situ Hybridization (ISH) by End-Use - Percentage Breakdown of Value Revenues for Hospitals & Diagnostic Labs, Pharma & Biotech Companies, Contract Research Organizations and Academic & Research Institutions for the Years 2012, 2021 & 2027
  • MIDDLE EAST
    • In Situ Hybridization (ISH) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2022 (E)
    • TABLE 244: Middle East Recent Past, Current & Future Analysis for In Situ Hybridization (ISH) by Technique - Fluorescence In Situ Hybridization (FISH) and Chromogenic In Situ Hybridization (CISH) - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 245: Middle East Historic Review for In Situ Hybridization (ISH) by Technique - Fluorescence In Situ Hybridization (FISH) and Chromogenic In Situ Hybridization (CISH) Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 246: Middle East 15-Year Perspective for In Situ Hybridization (ISH) by Technique - Percentage Breakdown of Value Revenues for Fluorescence In Situ Hybridization (FISH) and Chromogenic In Situ Hybridization (CISH) for the Years 2012, 2021 & 2027
    • TABLE 247: Middle East Recent Past, Current & Future Analysis for In Situ Hybridization (ISH) by Application - Cancer Diagnostics, Immunology, Neuroscience, Cytology and Infectious Disease Diagnostics - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 248: Middle East Historic Review for In Situ Hybridization (ISH) by Application - Cancer Diagnostics, Immunology, Neuroscience, Cytology and Infectious Disease Diagnostics Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 249: Middle East 15-Year Perspective for In Situ Hybridization (ISH) by Application - Percentage Breakdown of Value Revenues for Cancer Diagnostics, Immunology, Neuroscience, Cytology and Infectious Disease Diagnostics for the Years 2012, 2021 & 2027
    • TABLE 250: Middle East Recent Past, Current & Future Analysis for In Situ Hybridization (ISH) by End-Use - Hospitals & Diagnostic Labs, Pharma & Biotech Companies, Contract Research Organizations and Academic & Research Institutions - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 251: Middle East Historic Review for In Situ Hybridization (ISH) by End-Use - Hospitals & Diagnostic Labs, Pharma & Biotech Companies, Contract Research Organizations and Academic & Research Institutions Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 252: Middle East 15-Year Perspective for In Situ Hybridization (ISH) by End-Use - Percentage Breakdown of Value Revenues for Hospitals & Diagnostic Labs, Pharma & Biotech Companies, Contract Research Organizations and Academic & Research Institutions for the Years 2012, 2021 & 2027
    • TABLE 253: Middle East Recent Past, Current & Future Analysis for In Situ Hybridization (ISH) by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 254: Middle East Historic Review for In Situ Hybridization (ISH) by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 255: Middle East 15-Year Perspective for In Situ Hybridization (ISH) by Geographic Region - Percentage Breakdown of Value Revenues for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2012, 2021 & 2027
  • IRAN
    • TABLE 256: Iran Recent Past, Current & Future Analysis for In Situ Hybridization (ISH) by Technique - Fluorescence In Situ Hybridization (FISH) and Chromogenic In Situ Hybridization (CISH) - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 257: Iran Historic Review for In Situ Hybridization (ISH) by Technique - Fluorescence In Situ Hybridization (FISH) and Chromogenic In Situ Hybridization (CISH) Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 258: Iran 15-Year Perspective for In Situ Hybridization (ISH) by Technique - Percentage Breakdown of Value Revenues for Fluorescence In Situ Hybridization (FISH) and Chromogenic In Situ Hybridization (CISH) for the Years 2012, 2021 & 2027
    • TABLE 259: Iran Recent Past, Current & Future Analysis for In Situ Hybridization (ISH) by Application - Cancer Diagnostics, Immunology, Neuroscience, Cytology and Infectious Disease Diagnostics - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 260: Iran Historic Review for In Situ Hybridization (ISH) by Application - Cancer Diagnostics, Immunology, Neuroscience, Cytology and Infectious Disease Diagnostics Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 261: Iran 15-Year Perspective for In Situ Hybridization (ISH) by Application - Percentage Breakdown of Value Revenues for Cancer Diagnostics, Immunology, Neuroscience, Cytology and Infectious Disease Diagnostics for the Years 2012, 2021 & 2027
    • TABLE 262: Iran Recent Past, Current & Future Analysis for In Situ Hybridization (ISH) by End-Use - Hospitals & Diagnostic Labs, Pharma & Biotech Companies, Contract Research Organizations and Academic & Research Institutions - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 263: Iran Historic Review for In Situ Hybridization (ISH) by End-Use - Hospitals & Diagnostic Labs, Pharma & Biotech Companies, Contract Research Organizations and Academic & Research Institutions Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 264: Iran 15-Year Perspective for In Situ Hybridization (ISH) by End-Use - Percentage Breakdown of Value Revenues for Hospitals & Diagnostic Labs, Pharma & Biotech Companies, Contract Research Organizations and Academic & Research Institutions for the Years 2012, 2021 & 2027
  • ISRAEL
    • TABLE 265: Israel Recent Past, Current & Future Analysis for In Situ Hybridization (ISH) by Technique - Fluorescence In Situ Hybridization (FISH) and Chromogenic In Situ Hybridization (CISH) - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 266: Israel Historic Review for In Situ Hybridization (ISH) by Technique - Fluorescence In Situ Hybridization (FISH) and Chromogenic In Situ Hybridization (CISH) Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 267: Israel 15-Year Perspective for In Situ Hybridization (ISH) by Technique - Percentage Breakdown of Value Revenues for Fluorescence In Situ Hybridization (FISH) and Chromogenic In Situ Hybridization (CISH) for the Years 2012, 2021 & 2027
    • TABLE 268: Israel Recent Past, Current & Future Analysis for In Situ Hybridization (ISH) by Application - Cancer Diagnostics, Immunology, Neuroscience, Cytology and Infectious Disease Diagnostics - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 269: Israel Historic Review for In Situ Hybridization (ISH) by Application - Cancer Diagnostics, Immunology, Neuroscience, Cytology and Infectious Disease Diagnostics Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 270: Israel 15-Year Perspective for In Situ Hybridization (ISH) by Application - Percentage Breakdown of Value Revenues for Cancer Diagnostics, Immunology, Neuroscience, Cytology and Infectious Disease Diagnostics for the Years 2012, 2021 & 2027
    • TABLE 271: Israel Recent Past, Current & Future Analysis for In Situ Hybridization (ISH) by End-Use - Hospitals & Diagnostic Labs, Pharma & Biotech Companies, Contract Research Organizations and Academic & Research Institutions - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 272: Israel Historic Review for In Situ Hybridization (ISH) by End-Use - Hospitals & Diagnostic Labs, Pharma & Biotech Companies, Contract Research Organizations and Academic & Research Institutions Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 273: Israel 15-Year Perspective for In Situ Hybridization (ISH) by End-Use - Percentage Breakdown of Value Revenues for Hospitals & Diagnostic Labs, Pharma & Biotech Companies, Contract Research Organizations and Academic & Research Institutions for the Years 2012, 2021 & 2027
  • SAUDI ARABIA
    • TABLE 274: Saudi Arabia Recent Past, Current & Future Analysis for In Situ Hybridization (ISH) by Technique - Fluorescence In Situ Hybridization (FISH) and Chromogenic In Situ Hybridization (CISH) - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 275: Saudi Arabia Historic Review for In Situ Hybridization (ISH) by Technique - Fluorescence In Situ Hybridization (FISH) and Chromogenic In Situ Hybridization (CISH) Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 276: Saudi Arabia 15-Year Perspective for In Situ Hybridization (ISH) by Technique - Percentage Breakdown of Value Revenues for Fluorescence In Situ Hybridization (FISH) and Chromogenic In Situ Hybridization (CISH) for the Years 2012, 2021 & 2027
    • TABLE 277: Saudi Arabia Recent Past, Current & Future Analysis for In Situ Hybridization (ISH) by Application - Cancer Diagnostics, Immunology, Neuroscience, Cytology and Infectious Disease Diagnostics - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 278: Saudi Arabia Historic Review for In Situ Hybridization (ISH) by Application - Cancer Diagnostics, Immunology, Neuroscience, Cytology and Infectious Disease Diagnostics Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 279: Saudi Arabia 15-Year Perspective for In Situ Hybridization (ISH) by Application - Percentage Breakdown of Value Revenues for Cancer Diagnostics, Immunology, Neuroscience, Cytology and Infectious Disease Diagnostics for the Years 2012, 2021 & 2027
    • TABLE 280: Saudi Arabia Recent Past, Current & Future Analysis for In Situ Hybridization (ISH) by End-Use - Hospitals & Diagnostic Labs, Pharma & Biotech Companies, Contract Research Organizations and Academic & Research Institutions - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 281: Saudi Arabia Historic Review for In Situ Hybridization (ISH) by End-Use - Hospitals & Diagnostic Labs, Pharma & Biotech Companies, Contract Research Organizations and Academic & Research Institutions Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 282: Saudi Arabia 15-Year Perspective for In Situ Hybridization (ISH) by End-Use - Percentage Breakdown of Value Revenues for Hospitals & Diagnostic Labs, Pharma & Biotech Companies, Contract Research Organizations and Academic & Research Institutions for the Years 2012, 2021 & 2027
  • UNITED ARAB EMIRATES
    • TABLE 283: UAE Recent Past, Current & Future Analysis for In Situ Hybridization (ISH) by Technique - Fluorescence In Situ Hybridization (FISH) and Chromogenic In Situ Hybridization (CISH) - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 284: UAE Historic Review for In Situ Hybridization (ISH) by Technique - Fluorescence In Situ Hybridization (FISH) and Chromogenic In Situ Hybridization (CISH) Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 285: UAE 15-Year Perspective for In Situ Hybridization (ISH) by Technique - Percentage Breakdown of Value Revenues for Fluorescence In Situ Hybridization (FISH) and Chromogenic In Situ Hybridization (CISH) for the Years 2012, 2021 & 2027
    • TABLE 286: UAE Recent Past, Current & Future Analysis for In Situ Hybridization (ISH) by Application - Cancer Diagnostics, Immunology, Neuroscience, Cytology and Infectious Disease Diagnostics - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 287: UAE Historic Review for In Situ Hybridization (ISH) by Application - Cancer Diagnostics, Immunology, Neuroscience, Cytology and Infectious Disease Diagnostics Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 288: UAE 15-Year Perspective for In Situ Hybridization (ISH) by Application - Percentage Breakdown of Value Revenues for Cancer Diagnostics, Immunology, Neuroscience, Cytology and Infectious Disease Diagnostics for the Years 2012, 2021 & 2027
    • TABLE 289: UAE Recent Past, Current & Future Analysis for In Situ Hybridization (ISH) by End-Use - Hospitals & Diagnostic Labs, Pharma & Biotech Companies, Contract Research Organizations and Academic & Research Institutions - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 290: UAE Historic Review for In Situ Hybridization (ISH) by End-Use - Hospitals & Diagnostic Labs, Pharma & Biotech Companies, Contract Research Organizations and Academic & Research Institutions Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 291: UAE 15-Year Perspective for In Situ Hybridization (ISH) by End-Use - Percentage Breakdown of Value Revenues for Hospitals & Diagnostic Labs, Pharma & Biotech Companies, Contract Research Organizations and Academic & Research Institutions for the Years 2012, 2021 & 2027
  • REST OF MIDDLE EAST
    • TABLE 292: Rest of Middle East Recent Past, Current & Future Analysis for In Situ Hybridization (ISH) by Technique - Fluorescence In Situ Hybridization (FISH) and Chromogenic In Situ Hybridization (CISH) - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 293: Rest of Middle East Historic Review for In Situ Hybridization (ISH) by Technique - Fluorescence In Situ Hybridization (FISH) and Chromogenic In Situ Hybridization (CISH) Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 294: Rest of Middle East 15-Year Perspective for In Situ Hybridization (ISH) by Technique - Percentage Breakdown of Value Revenues for Fluorescence In Situ Hybridization (FISH) and Chromogenic In Situ Hybridization (CISH) for the Years 2012, 2021 & 2027
    • TABLE 295: Rest of Middle East Recent Past, Current & Future Analysis for In Situ Hybridization (ISH) by Application - Cancer Diagnostics, Immunology, Neuroscience, Cytology and Infectious Disease Diagnostics - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 296: Rest of Middle East Historic Review for In Situ Hybridization (ISH) by Application - Cancer Diagnostics, Immunology, Neuroscience, Cytology and Infectious Disease Diagnostics Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 297: Rest of Middle East 15-Year Perspective for In Situ Hybridization (ISH) by Application - Percentage Breakdown of Value Revenues for Cancer Diagnostics, Immunology, Neuroscience, Cytology and Infectious Disease Diagnostics for the Years 2012, 2021 & 2027
    • TABLE 298: Rest of Middle East Recent Past, Current & Future Analysis for In Situ Hybridization (ISH) by End-Use - Hospitals & Diagnostic Labs, Pharma & Biotech Companies, Contract Research Organizations and Academic & Research Institutions - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 299: Rest of Middle East Historic Review for In Situ Hybridization (ISH) by End-Use - Hospitals & Diagnostic Labs, Pharma & Biotech Companies, Contract Research Organizations and Academic & Research Institutions Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 300: Rest of Middle East 15-Year Perspective for In Situ Hybridization (ISH) by End-Use - Percentage Breakdown of Value Revenues for Hospitals & Diagnostic Labs, Pharma & Biotech Companies, Contract Research Organizations and Academic & Research Institutions for the Years 2012, 2021 & 2027
  • AFRICA
    • In Situ Hybridization (ISH) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2022 (E)
    • TABLE 301: Africa Recent Past, Current & Future Analysis for In Situ Hybridization (ISH) by Technique - Fluorescence In Situ Hybridization (FISH) and Chromogenic In Situ Hybridization (CISH) - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 302: Africa Historic Review for In Situ Hybridization (ISH) by Technique - Fluorescence In Situ Hybridization (FISH) and Chromogenic In Situ Hybridization (CISH) Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 303: Africa 15-Year Perspective for In Situ Hybridization (ISH) by Technique - Percentage Breakdown of Value Revenues for Fluorescence In Situ Hybridization (FISH) and Chromogenic In Situ Hybridization (CISH) for the Years 2012, 2021 & 2027
    • TABLE 304: Africa Recent Past, Current & Future Analysis for In Situ Hybridization (ISH) by Application - Cancer Diagnostics, Immunology, Neuroscience, Cytology and Infectious Disease Diagnostics - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 305: Africa Historic Review for In Situ Hybridization (ISH) by Application - Cancer Diagnostics, Immunology, Neuroscience, Cytology and Infectious Disease Diagnostics Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 306: Africa 15-Year Perspective for In Situ Hybridization (ISH) by Application - Percentage Breakdown of Value Revenues for Cancer Diagnostics, Immunology, Neuroscience, Cytology and Infectious Disease Diagnostics for the Years 2012, 2021 & 2027
    • TABLE 307: Africa Recent Past, Current & Future Analysis for In Situ Hybridization (ISH) by End-Use - Hospitals & Diagnostic Labs, Pharma & Biotech Companies, Contract Research Organizations and Academic & Research Institutions - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 308: Africa Historic Review for In Situ Hybridization (ISH) by End-Use - Hospitals & Diagnostic Labs, Pharma & Biotech Companies, Contract Research Organizations and Academic & Research Institutions Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 309: Africa 15-Year Perspective for In Situ Hybridization (ISH) by End-Use - Percentage Breakdown of Value Revenues for Hospitals & Diagnostic Labs, Pharma & Biotech Companies, Contract Research Organizations and Academic & Research Institutions for the Years 2012, 2021 & 2027

IV. COMPETITION

  • Total Companies Profiled: 38